Search Results

FDA widens approval of Vertex's CRISPR medicine to treat beta thalassemia.

• Authors : Pagliarulo, Ned

Subjects: DRUG approval; BETA-Thalassemia; THALASSEMIA treatmentVERTEX Pharmaceuticals Inc. 602478257 VERTEX Pharmaceuticals Inc. VERTEX Pharmaceuticals Inc. 602478257 602478257 VERTEX Pharmaceuticals Inc. 602478257 VRTX

• Source: BioPharma Dive. 1/16/2024, p1-1. 1p.

Record details

FDA widens approval of Vertex's CRISPR medicine to treat beta thalassemia.

Subjects: DRUG approval; BETA-Thalassemia; THALASSEMIA treatmentVERTEX Pharmaceuticals Inc. 602478257 VERTEX Pharmaceuticals Inc. VERTEX Pharmaceuticals Inc. 602478257 602478257 VERTEX Pharmaceuticals Inc. 602478257 VRTX

• Source: BioPharma Dive. 1/16/2024, p1-1. 1p.

Record details

World's first CRISPR medicine approved in UK for sickle cell, beta thalassemia.

• Authors : Pagliarulo, Ned

Subjects: CRISPRS; DRUG approval; BETA-ThalassemiaUNITED Kingdom

• Source: BioPharma Dive. 11/16/2023, p1-3. 3p.

Record details

He Never Saw It Coming.

• Authors : Dunbar, Mark T.; Gomez, Nabila

Subjects: BLINDNESS; RETINAL artery occlusion; RETINAL vein occlusion

• Source: Review of Optometry. 8/15/2016, Vol. 153 Issue 8, p69-72. 4p.

Record details

Bluebird, short on cash, takes on $175M in debt financing.

• Authors : Alvarado, Delilah

Subjects: *CORPORATE debt financing; *BIOTECHNOLOGY industries; GENE therapyHERCULES Capital Inc.

• Source: BioPharma Dive. 3/18/2024, pN.PAG-N.PAG. 1p.

Record details

Assessing the Success of CRISPR Gene Therapies Using ddPCR.

• Authors : Alsarraj, Marwan¹

Subjects: *TECHNOLOGY; GENETIC mutation; TREATMENT effectiveness

• Source: Pharmaceutical Technology Europe. May2022, Vol. 34 Issue 5, p15-16. 2p.

Record details

US government declines to clear Bluebird fertility support for Zynteglo patients.

• Authors : Pagliarulo, Ned

Subjects: *HEALTH insurance; INFERTILITY treatment; GENE therapyBLUEBIRD Bio Inc.

• Source: BioPharma Dive. 7/22/2024, pN.PAG-N.PAG. 1p.

Record details

Biopharmaceutical Frontiers.

• Authors : Galbraith, Daniel¹

Subjects: *DIFFUSION of innovations; *INTERPROFESSIONAL relations; *PHARMACEUTICAL industry

• Source: Pharmaceutical Technology Europe. Sep2024, Vol. 36 Issue 8, p18-19. 2p.

Record details

2024 PREDICTIONS.

• Source: Managed Healthcare Executive. Jan2024, Vol. 34 Issue 1, p20-23. 4p.

Record details

Risks and Rewards of Investing in RNA-based Genetic Medicine Manufacturing: Collaboration is a key component to achieving long-term success with genetic medicines.

• Authors : Lewis, John¹

Subjects: *INVESTMENTS; *COVID-19 vaccines; *LABOR demandUNITED States. Food & Drug Administration

• Source: Pharmaceutical Technology Europe. Dec2023, Vol. 35 Issue 12, p22-24. 3p.

Record details